Oligomer-protein tyrosine kinase inhibitor conjugates
View Patent ↗The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water soluble, non peptidic oligomer.
1. A compound, having the following structure:
wherein:
X is a spacer moiety; and
POLY is a water-soluble, non-peptidic oligomer having from about 1 to about 30 monomers.
2. The compound of claim 1 , wherein: X is a a spacer moiety that includes a bivalent peptidic moiety of an amino acid.
3. The compound of claim 1 , wherein the water-soluble, non-peptidic oligomer is a poly(alkylene oxide).
4. The compound of claim 3 , wherein the poly(alkylene oxide) is a poly(ethylene oxide).
5. The compound of claim 1 , wherein the water-soluble, non-peptidic oligomer has from about 1 to about 10 monomers.
6. The compound of claim 4 , wherein the poly(alkylene oxide) includes an alkoxy or hydroxy end-capping moiety.
7. A composition comprising a compound of claim 1 , and optionally, a pharmaceutically acceptable excipient.
8. A composition of matter comprising a compound of claim 1 , wherein the compound is present in a dosage form.
9. A compound of claim 1 , having the following structure
wherein n is 1 to 30; and X is a peptidic moiety of a bivalent amino acid.
10. A compound of claim 1 , having a structure selected from
wherein n is 1 to 30.
11. A composition comprising a compound of claim 9 , and optionally, a pharmaceutically acceptable excipient.
12. A composition of matter comprising a compound of claim 9 , wherein the compound is present in a dosage form.